Deferoxamine Dosing for Acute Iron Toxicity in Pediatric Patients

Safety Considerations

• Growth monitoring is essential in pediatric patients receiving deferoxamine, as serious adverse events occur particularly when deferoxamine doses are high relative to iron burden, according to the American Heart Association 1, 2, 3
• Ophthalmologic and audiological testing should be performed in pediatric patients receiving deferoxamine, as sensorineural deafness and visual disturbances are recognized toxicities, as recommended by the American Heart Association 1, 4, 5
• Skeletal abnormalities and growth retardation are documented adverse effects in pediatric patients receiving deferoxamine, highlighting the need for careful monitoring and dose adjustment, as noted by the American Heart Association 1, 2, 4
• Infection risk, including Yersinia and Klebsiella infections, should be watched for in patients treated with deferoxamine, according to the American Heart Association 1, 2, 3, 5